•
•
•
•
•
•
•
•
Country
US
Industry
Health Care
Market Cap
Small Cap
Num. Employees
526
IPO Date
May 6, 2016
Country
US
Industry
Health Care
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 526 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. The company is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. The company is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
investing.com
22.22%
Finnhub
16.67%
fr.investing.com
16.67%
Others
44.44%
The most substantial move of the day was the sale of Robinhood Markets Inc (NASDAQ:HOOD) shares, with a total of 1,421,431 shares offloaded across three ARK funds, amounting to a considerable $33,147,770.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Related Stocks
Related Stocks
Stocks being mentioned with NTLA
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Slightly Bearish